Iho Corporation

1. Janssen Research & Development, LLC $526,398 94 payments
2. Daiichi Sankyo Inc. $368,018 48 payments
3. AstraZeneca Pharmaceuticals LP $297,187 10 payments
4. Eli Lilly and Company $296,696 24 payments
5. AbbVie, Inc. $269,940 78 payments
6. AstraZeneca UK Limited $241,736 3 payments
7. Merck Sharp & Dohme Corporation $126,278 14 payments
8. Celgene Corporation $109,754 9 payments
9. Aadi Bioscience, Inc. $108,617 22 payments
10. Boehringer Ingelheim Pharmaceuticals, Inc. $106,420 37 payments

1. Ds1062-A-U304 $287,838 35 payments
2. CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $241,736 3 payments
3. A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer $197,029 12 payments
4. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $156,483 8 payments
5. A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole $128,359 3 payments
6. A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions $118,253 21 payments
7. A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes $108,617 22 payments
8. Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma $102,685 36 payments
9. A Phase 1b2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration Resistant Prostate Cancer $80,293 39 payments
10. Ds1062-A-U303 $78,980 12 payments

1. Non-patient care $75,589 27 payments
2. Patient care $16,001 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.